1. Alanore LF, Roujeau JC.

Inflammatory disease based on abnormal humoral reactivity

and other inflammatory disease: General consideration. Wolff K, Goldsmith LA, Katz
SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick Dermatology in General
Medicine. 8th ed. USA: Mc graw hill; 2012. Page 608-616.
2. Wojnarowska F, Venning VA. Immunobullous Disease. Burns T, Breathnach S, Cox N,
Griffiths C, Rooks Textbook of Dermatology. 8th. Blacwell Scienc : Italy. 2010. Page
40.26-32
3. Wolff, K., et al. Fitzpatricks Color Atlas and Synopsis of Clinical Dermatology, 7th ed.
Mc Graw Hill : USA. 2013. Page 107-108.
4. Bystrim JC, Chan YC, Chu J at all. Chronic Blistering Dermatoses. James WD, Berger
TG, Elston DM. Andrews Diseases Of The Skin: Clinical Dermatology. 10th. Saunders
Elsevier. USA : 2006. Page 466-467
5. Kasperkiewicz, M., et al. Pemphigoid Disease : Pathogenesis, Diagnosis, and
Treatment. Informa Healthcare : UK. 2012.
6. Melita, N., dkk. Terapi Ajuvan pada Pemfigoid Bulosa dalam Majalah Ilmiah Resmi
Perhimpunan Dokter Spesialis Kulit & Kelamin Indonesia (PERDOSKI). MDVI :
Jakarta. 2012. Hal. 62-69.
7. Venning, VA., et al. Guidelines for the Management of Bullous Pemphigoid. British
Journal of Dermatology. 2012. Page 1200-1214.
8. Schmidt, E., et al. The Diagnosis and Treatment of Autoimmune Blistering Skin
Diseases. 2011. Page 399-404.
9. Murrell, D., et al. Definition and Outcome Measures for Bullous Pemphigoid :
Recommendations by an International Panel of Experts. National Institutes of Health.
2012. Page 2-6.
10. Feliciani, C., et al. Management of Bullous Pemphigoid : The European Dermatology
Forum Consensus in Collaboration with the European Academy of Dermatology and
Venereology. British Jornal of Dermatology. 2014. Page 867-877.